Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Julphar
Medtronic
Healthtrust
Novartis
Cerilliant
Merck
Cantor Fitzgerald
AstraZeneca
Farmers Insurance

Generated: January 17, 2018

DrugPatentWatch Database Preview

Forest Labs Llc Company Profile

« Back to Dashboard

What is the competitive landscape for FOREST LABS LLC, and what generic alternatives to FOREST LABS LLC drugs are available?

FOREST LABS LLC has ten approved drugs.

There are thirty-five US patents protecting FOREST LABS LLC drugs and there have been seven Paragraph IV challenges on FOREST LABS LLC drugs in the past three years.

There are three hundred and fifty-eight patent family members on FOREST LABS LLC drugs in forty-five countries and eighteen supplementary protection certificates in ten countries.

Summary for Forest Labs Llc
International Patents:358
US Patents:35
Tradenames:9
Ingredients:8
NDAs:10

Drugs and US Patents for Forest Labs Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Llc SAPHRIS asenapine maleate TABLET;SUBLINGUAL 022117-001 Aug 13, 2009 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Forest Labs Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-002 Dec 23, 2014 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Forest Labs Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-001 Dec 23, 2014 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Forest Labs Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-001 Dec 23, 2014 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Forest Labs Llc NAMENDA memantine hydrochloride SOLUTION;ORAL 021627-001 Apr 18, 2005 AA RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Forest Labs Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-002 Dec 23, 2014 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-002 Jun 21, 2010 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Forest Labs Llc BYVALSON nebivolol hydrochloride; valsartan TABLET;ORAL 206302-001 Jun 3, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Forest Labs Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-004 Jul 18, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Forest Labs Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-002 Dec 23, 2014 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Forest Labs Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-001 Jun 21, 2010 ➤ Subscribe ➤ Subscribe
Forest Labs Llc PYLERA bismuth subcitrate potassium; metronidazole; tetracycline CAPSULE;ORAL 050786-001 Sep 28, 2006 ➤ Subscribe ➤ Subscribe
Forest Labs Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-002 Dec 23, 2014 ➤ Subscribe ➤ Subscribe
Forest Labs Llc NAMENDA memantine hydrochloride TABLET;ORAL 021487-002 Oct 16, 2003 ➤ Subscribe ➤ Subscribe
Forest Labs Llc NAMENDA memantine hydrochloride SOLUTION;ORAL 021627-001 Apr 18, 2005 ➤ Subscribe ➤ Subscribe
Forest Labs Llc NAMENDA XR memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022525-004 Jun 21, 2010 ➤ Subscribe ➤ Subscribe
Forest Labs Llc PYLERA bismuth subcitrate potassium; metronidazole; tetracycline CAPSULE;ORAL 050786-001 Sep 28, 2006 ➤ Subscribe ➤ Subscribe
Forest Labs Llc NAMENDA memantine hydrochloride TABLET;ORAL 021487-001 Oct 16, 2003 ➤ Subscribe ➤ Subscribe
Forest Labs Llc NAMENDA memantine hydrochloride TABLET;ORAL 021487-002 Oct 16, 2003 ➤ Subscribe ➤ Subscribe
Forest Labs Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-001 Dec 23, 2014 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for FOREST LABS LLC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Sublingual Tablets 2.5 mg ➤ Subscribe 7/27/2017
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 6/9/2017
➤ Subscribe Capsules 7 mg/10 mg ➤ Subscribe 9/26/2016
➤ Subscribe Capsules 21 mg/10 mg ➤ Subscribe 9/23/2016
➤ Subscribe Capsules 145 mcg and 290 mcg ➤ Subscribe 8/30/2016
➤ Subscribe Capsules 14 mg/10 mg and 28 mg/10 mg ➤ Subscribe 5/18/2015
➤ Subscribe Tablets 10 mg, 20 mg, and 40 mg ➤ Subscribe 1/21/2015
➤ Subscribe Capsules 140 mg/125 mg/ 125 mg ➤ Subscribe 8/12/2014
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg, and 28 mg ➤ Subscribe 8/16/2013
➤ Subscribe Sublingual Tablets 5 mg and 10 mg ➤ Subscribe 8/13/2013
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg ➤ Subscribe 6/17/2013
➤ Subscribe Extended-release Capsules 28 mg ➤ Subscribe 6/12/2013
➤ Subscribe Extended-release Capsules 7 mg, 14 mg, 21 mg, and 28 mg ➤ Subscribe 6/10/2013
➤ Subscribe Suppository 1000 mg ➤ Subscribe 5/24/2013
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 10/16/2007

Non-Orange Book US Patents for Forest Labs Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,318,744 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride ➤ Subscribe
7,772,188 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
2,012,045,508 ➤ Subscribe
9,624,204 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride ➤ Subscribe
8,921,375 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride ➤ Subscribe
2,014,073,571 ➤ Subscribe
8,927,552 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride ➤ Subscribe
7,541,384 Mesalamine suppository ➤ Subscribe
2,012,058,182 ➤ Subscribe
7,910,546 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Forest Labs Llc Drugs

Supplementary Protection Certificates for Forest Labs Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1998 Austria ➤ Subscribe PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214
C/GB02/046 United Kingdom ➤ Subscribe PRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515
C/GB97/023 United Kingdom ➤ Subscribe PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
201 Luxembourg ➤ Subscribe PRODUCT NAME: LINACLOTIDE ET TOUTE FORME THERAPEUTIQUE EQUIVALENTE DE CELUICI,PROTETE PAR LE BREVET DE BASE,Y COMPRIS DES SELS PHARMACEUTIQUEMENT ACCEPTABLES
90024-6 Sweden ➤ Subscribe PRODUCT NAME: LINAKLOTID; REG. NO/DATE: EU/1/12/801/001 20121126
2013013 Lithuania ➤ Subscribe PRODUCT NAME: LINACLOTIDUM; REGISTRATION NO/DATE: EU/1/12/801/001 - EU/1/12/801/004 20121126
2013 00027 Denmark ➤ Subscribe
00594 Netherlands ➤ Subscribe PRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126
0593 Netherlands ➤ Subscribe PRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126
02C/035 Belgium ➤ Subscribe PRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Teva
US Army
Chubb
Deloitte
Johnson and Johnson
Chinese Patent Office
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot